Tina Klitmøller Agander

Medicine & Life Sciences

1. Acinar Cell Carcinoma 19%
2. Adenocarcinoma 42%
3. Adenoid Cystic Carcinoma 87%
4. alpha-Synuclein 15%
5. Ambulatory Care Facilities 12%
6. Basal Ganglia 13%
7. Brain 19%
8. Carcinoma 60%
9. Cerebellar Nuclei 13%
10. Clinical Protocols 12%
11. Denmark 99%
12. Epidemiology 12%
13. Feasibility Studies 13%
14. Fine Needle Biopsy 17%
15. Gene Fusion 33%
16. Head and Neck Neoplasms 32%
17. High-Throughput Nucleotide Sequencing 14%
18. Histology 24%
19. Hypopharyngeal Neoplasms 26%
20. Incidence 55%
21. Lacrimal Apparatus 15%
22. Laryngeal Neoplasms 17%
23. Magnetic Resonance Imaging 15%
24. Margins of Excision 28%
25. Medical Oncology 15%
26. MicroRNAs 32%
27. Multiple System Atrophy 68%
28. Mutation 36%
29. Nasal Cavity 14%
30. Neck 13%
31. Neoplasm Metastasis 32%
32. Neoplasms 50%
33. Oropharyngeal Neoplasms 56%
34. Palate 15%
35. Parotid Gland 21%
36. Pleomorphic Adenoma 17%
37. Population 20%
38. Recurrence 27%
39. Salivary Glands 100%
40. Squamous Cell Carcinoma 29%
41. Sublingual Gland 19%
42. Submandibular Gland 18%
43. Substantia Nigra 14%
44. Survival 65%
45. Survival Analysis 14%
46. Survival Rate 17%
47. Thyroid Neoplasms 26%
48. Toll-Like Receptors 14%
49. Tongue Neoplasms 23%
50. Xerostomia 16%